1. Home
  2. AMST vs NXL Comparison

AMST vs NXL Comparison

Compare AMST & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

HOLD

Current Price

$1.33

Market Cap

8.2M

Sector

Technology

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.46

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMST
NXL
Founded
2017
2010
Country
United States
United States
Employees
N/A
7
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
8.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AMST
NXL
Price
$1.33
$0.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.6K
362.7K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
40.46
N/A
EPS
N/A
N/A
Revenue
$110,459.00
N/A
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$0.33
52 Week High
$4.78
$2.00

Technical Indicators

Market Signals
Indicator
AMST
NXL
Relative Strength Index (RSI) 27.04 55.19
Support Level N/A $0.35
Resistance Level $1.92 $0.46
Average True Range (ATR) 0.10 0.04
MACD -0.02 0.01
Stochastic Oscillator 6.71 67.84

Price Performance

Historical Comparison
AMST
NXL

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: